LNTH earnings analysis
What we found in LNTH's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Lantheus reported a solid Q1 2026 with revenue of $377.3 million, exceeding estimates and achieving an EPS of $1.80, reflecting a 62.3% increase in net income year-over-year. However, gross profit declined slightly, primarily due to price reductions for PYLARIFY despite strong revenues in new segments like Neuraceq and DEFINITY.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Q1 2026 Revenue Beat
- Lantheus achieved revenue of $377.3 million, exceeding consensus estimates of $355.2 million.
- Q1 2026 EPS Beat
- The company reported EPS of $1.80, surpassing the estimated $1.19.
- Strong Free Cash Flow
- Positive operating cash flow of $125.1 million was recorded, compared to $107.6 million in Q1 2025.
- Diverse Revenue Streams
- New products Neuraceq and DEFINITY drove growth, with Neuraceq contributing $35.4 million in newly included revenues.
- Strategic Business Sales
- The sale of the SPECT business contributed $59.3 million to gains, bolstering cash reserves.
- Increase in Accounts Payable
- A timely increase in accounts payable helped improve cash flow management.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Decline in PYLARIFY Sales
- PYLARIFY revenues fell by $16.7 million (6.5%) year-over-year to $240.9 million due to pricing pressures.
- Regulatory Timeline Risks for LNTH-2501
- FDA extended the review of LNTH-2501's NDA, impacting expected timelines for product launch.
- Integration Challenges Post-Acquisitions
- The acquisitions of Evergreen and Lantheus Biosciences may face operational integration risks that could affect future performance.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $1.8
- Gross margin
- 61.3%
- Operating margin
- 21.5%
- Segment
- Oncology
- Segment
- Neurology
- Segment
- Cardiology
- Segment
- Strategic Partnerships
What they said about what is next.
The company reaffirmed full-year guidance for revenue between $1.4 billion and $1.45 billion and adjusted EPS between $5.00 and $5.25.
The filing reads better than the one before it.
What came before.
- 10-K · February 26, 2026
- Lantheus’ 10-K emphasizes a strategy focused on PET radiodiagnostics and microbubbles, highlighted by multiple 2025 acquisitions (Life Molecular and Evergreen) and the post-period divestiture of its SPECT business to…
- 10-Q · May 7, 2025
- Lantheus reported revenue of $372,764,000 for the three months ended March 31, 2025, up $2,789,000 versus $369,975,000 in Q1 2024, while diluted EPS fell to $1.02 from $1.87 a year ago. Gross margin was 63.8% and…
- 10-K · February 26, 2025
- Lantheus describes a deliberate strategy to evolve into a fully integrated radiopharmaceutical company, expanding through targeted M&A and in‑licensing while commercializing core products (PYLARIFY, DEFINITY) and…
- 10-Q · July 31, 2024
- Lantheus reported Q2 2024 revenue of $394.091M, up $72.391M (22.5%) versus Q2 2023, driven primarily by PYLARIFY growth. Gross margin was stable at 64.9% but operating margin and EPS compressed as operating expenses…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LNTH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever